It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

pharmaceuticals

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
AstraZeneca bets $6.9 billion that Daiichi Sankyo therapy will transform cancer treatment

Business / Corporate Mar 29, 2019

AstraZeneca bets $6.9 billion that Daiichi Sankyo therapy will transform cancer treatment

Britain’s AstraZeneca’s biggest deal in recent memory give it access to the Japanese drugmaker’s promising but difficult to pronounce cancer treatment: trastuzumab deruxtecan.

Business Jan 2, 2019

China's generic drug makers struggle to survive bulk-buy policy onslaught

Even after a plunge last month that wiped $46 billion off Chinese health-care stocks, domestic drug makers may be far from their floor as a Beijing-led policy shift gathers pace. China's plan to drive down generic drug prices through a centralized bulk procurement program is ...

Japan's Takeda to seek shareholder approval of Shire purchase plan Dec. 5

Business / Corporate Nov 12, 2018

Japan's Takeda to seek shareholder approval of Shire purchase plan Dec. 5

Takeda Pharmaceutical Co. said it will convene an extraordinary meeting of shareholders Dec. 5 to win approval for its plan to acquire Irish drugmaker Shire PLC that would make it a global top 10 company in the industry. But the Japanese pharmaceutical may face criticism ...

A blue pill is stopping HIV, world-first study shows

Asia Pacific / Science & Health Oct 18, 2018

A blue pill is stopping HIV, world-first study shows

An antiviral pill taken daily by thousands of men across Sydney and other parts of Australia led to a globally unprecedented reduction in new HIV cases, showing that a targeted, preventative approach may accelerate progress on ending the AIDS epidemic. New cases of HIV among ...

Business Jul 7, 2018

Alzheimer's research gets glimmer of hope, but not for first time

For the few drugmakers that haven't given up on the decadeslong, elusive quest for a cure of Alzheimer's disease, each piece of news is a small signpost along a possible path to success — and billions of dollars in potential sales. That helps explain the ...

World / Science & Health Dec 9, 2017

Pfizer's breast cancer drug found to be superior to chemotherapy in Phase III study

Patients with advanced breast cancer tied to an inherited gene mutation who were treated with an experimental Pfizer drug went about three months longer before their disease worsened than those who received chemotherapy in a late-stage study, according to data released Friday. The drug, talazoparib, ...

Seirogan's trumpet melody is now a registered trademark

Language | NEWS IN NIHONGO Nov 6, 2017

Seirogan's trumpet melody is now a registered trademark

A trumpet melody used in the commercial for Taiko Pharmaceutical's Seirogan was registered as a trademark at the end of September, the first solely musical trademark to be registered in Japan.

Finance Ministry proposes cuts in medical fees and reductions in cost of new drugs

National / Science & Health Oct 26, 2017

Finance Ministry proposes cuts in medical fees and reductions in cost of new drugs

The Finance Ministry on Wednesday proposed reducing the fees charged by medical institutions, to curb social security costs which have ballooned due to the country's rapidly aging population. The fees, made up of drug and medical service costs, need to be slashed by at least ...

Japan's health ministry enlists anime hero in battle against overuse of antibiotics

National / Science & Health | A MATTER OF HEALTH Oct 11, 2017

Japan's health ministry enlists anime hero in battle against overuse of antibiotics

by Tomoko Otake

The health ministry has enlisted the help of Amuro, the protagonist of the popular anime series "Mobile Suit Gundam," in its battle against the misuse and overuse of antibiotics — which can lead to antimicrobial resistance (AMR). Amuro Ray's famous phrase, "Amuro ikimasu!" ("Amuro is ...

Opioids demand rises in Japan as seniors use drugs to ease pain and improve quality of life

Business / Corporate Sep 29, 2017

Opioids demand rises in Japan as seniors use drugs to ease pain and improve quality of life

by Kanoko Matsuyama

Selling painkillers in Japan used to be like pulling teeth. That was until baby boomers discovered how analgesics could take the sting from arthritis, diabetic nerve damage and the ravages of cancer. Now demand is taking off and drugmakers are introducing new products to a ...

Japan's push to curb drug costs seen risking trade row with U.S.

Business Sep 14, 2017

Japan's push to curb drug costs seen risking trade row with U.S.

by Connor Cislo and Maiko Takahashi

Japan's effort to rein in soaring health-care costs threatens to become a source of tension in economic relations with the U.S. after running into opposition from the American pharmaceutical industry. While the U.S. Commerce Department sees Japan's drug market, the world's third-largest, as the top ...

Yamamoto Chemical drug mixed with cheaper China-sourced stocks, dodging ministry oversight

National / Science & Health Jun 22, 2017

Yamamoto Chemical drug mixed with cheaper China-sourced stocks, dodging ministry oversight

Pharmaceutical manufacturer added acetaminophen imported from China to its own drug without the proper paperwork in an apparent bid to cut costs.

« 1 … 37 38 39 … 42 »
  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Nadeshiko Japan downs Costa Rica to move into knockout stage

    Thumbnail image
  • AI is rewriting the rules of $200 billion games industry

    Thumbnail image
  • Indonesia rides EV rush to domestic IPO boom

    Thumbnail image
  • 'Japan's Anatolia' becomes a home away from home for Kurds and Turks

    Thumbnail image
  • From 'Young General' to 'Supreme Leader': The evolution of Kim Jong Un

    Thumbnail image

PODCAST

  • DEEP DIVE

    A tale of two Fujis: Bullet climbs, crowds and Lizzo

Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times